| Literature DB >> 27398218 |
Minnie Chan1, Adah Almutairi2.
Abstract
In the past few decades, advances in imaging equipment and protocols have expanded the role of imaging in in vivo diagnosis and disease management, especially in cancer. Traditional imaging agents have rapid clearance and low specificity for disease detection. To improve accuracy in disease identification, localization and assessment, novel nanomaterials are frequently explored as imaging agents to achieve high detection specificity and sensitivity. A promising material for this purpose are hydrogel nanoparticles, whose high hydrophilicity, biocompatibility, and tunable size in the nanometer range make them ideal for imaging. These nanogels (10 to 200 nm) can circumvent uptake by the reticuloendothelial system, allowing longer circulation times than small molecules. In addition, their size/surface properties can be further tailored to optimize their pharmacokinetics for imaging of a particular disease. Herein, we provide a comprehensive review of nanogels as imaging agents in various modalities with sources of signal spanning the electromagnetic spectrum, including MRI, NIR, UV-vis, and PET. Many materials and formulation methods will be reviewed to highlight the versatility of nanogels as imaging agents.Entities:
Year: 2015 PMID: 27398218 PMCID: PMC4906372 DOI: 10.1039/c5mh00161g
Source DB: PubMed Journal: Mater Horiz ISSN: 2051-6347 Impact factor: 13.266
Fig. 1Imaging modalities with sources of radiation/signal spanning the electromagnetic spectrum.
Fig. 2Nanogel formulation strategies. (A) Hydrophilic monomers and crosslinkers in a water-in-oil emulsion, stabilized by surfactants. Upon the addition of a catalyst, polymerization occurs within the emulsion droplets, forming nanogels. (B) Hydrophilic polymer modified with functional groups that allow physical/chemical crosslinking to form nanogels. (C) Polymer modified with hydrophobic moieties for self-assembly into nanogels. (D) Positively and negatively charged polymer self-assembly through electrostatic interaction. (E) Polymerization of monomers and crosslinkers shell or self-assembly of polymer modified with hydrophobic moieties in presence of nucleation sites.
(a) MRI contrast agents – part I. (b) MRI contrast agents – part II
| Imaging modality | Dye/contrast agent | Means of incorporation | Polymer components | Responsive size change | Responsive imaging property | Formulation method | Size (nm) | Targeting group | Cells/ | Therapeutics | Ref. |
| (a) | |||||||||||
| MRI (Gd-based) | Gd-DOTA | As chemical crosslinkers | PAA chemically crosslinked by DTPA/DOTA crosslinkers | N/A | N/A | A | 54–85 | N/A | N/A | N/A |
|
| MRI (Gd-based) | Gd-DTPA | Conjugation | Poly(PEGMA)-crosslink by ethylene glycol bisacrylamide | N/A | N/A | B | 10 | N/A | Imaging of blood vessel in mice | N/A |
|
| MRI (Gd-based) | Gd-DTPA | Electrostatic | PAA + chitosan | pH (zeta potential) | N/A | A + D | 220 | N/A | Imaging of rabbit brain and liver | N/A |
|
| MRI (Gd-based) + NIR fluorescence | Gd3+ Cy 5.5 | As physical crosslinkers (electrostatic) Conjugation | PEI | N/A | N/A | B | 159 ± 62 | N/A | Imaging of SCC7 tumor of mice | N/A |
|
| MRI (Fe3O4) | Fe3O4 | Encapsulation | Dextrin-VA-SC16 | N/A | N/A | C | 100 | N/A | Uptake in Murine bone marrow-derived macrophages | N/A |
|
| MRI (Fe3O4) | Fe3O4 | As core from which polymer matrix was built on | Poly(PEGMA) crosslinked with MBA | N/A | N/A | A + E | 68 | N/A | N/A | Doxorubicin |
|
| MRI (Fe3O4) | Fe3O4 | As core from which polymer matrix was built on | Poly(AEM·HCl) crosslinked with MBA | N/A | N/A | A + E | 19 | N/A | Healthy mice | N/A |
|
| MRI (Fe3O4) | Fe3O4 | Encapsulation | Poly(NIPAAm- | Temperature and pH | N/A | A + E | 237 (pH 2.7) to 387 (7.6) 25 °C | N/A | Cytotoxicity on HeLa cells | Doxorubicin |
|
| MRI (Fe3O4) | Fe3O4 | Encapsulation | Self-assembly of poly(AAc- | pH and magnetic hyperthermia | N/A | C + D | 243 (pH 4.7) to 221 (pH 7.4) 20 °C | Folate acid | Therapeutic efficacy on tumor-bearing mice | Doxorubicin |
|
| (b) | |||||||||||
| MRI (Fe3O4) + UV fluorescence | Fe3O4 fluorescein | Encapsulation Conjugation | PBMA- | N/A | N/A | C | 131–250 | N/A | N/A | N/A |
|
| MRI (Fe3O4) + UV fluorescence | Fe3O4 fluorescein | Encapsulation Conjugation | pCBMA with disulfide crosslinks | Disulfide: reducing environment | N/A | A + E | 110 | RGD | Uptake in Macrophage cell | Fluorescently labeled dextran (model) |
|
| MRI (Fe3O4) + NIR fluorescence | Fe3O4 Cy5.5 | Encapsulation Conjugation | Poly(NIPAAm- | pH and/temperature | N/A | A + E | 100 (pH 6.8) to 85 (pH 7.4) at 37 °C | Lactoferrin | Imaging of C6 glioma in rats | N/A |
|
| MRI (Fe3O4) + UV fluorescence | Fe3O4 Dil | Encapsulation Encapsulation | Self-assembled poly(NIPAAm- | Temperature | N/A | C + D | 200 | N/A | Imaging of mice injected with nanogels-loaded hMSC | EPFG expression plasmid |
|
| MRI (Fe3O4) + UV fluorescence | MnFe2O4 fluorescent Schiff base bond (C | As core from which polymer graft on Part of polymer matrix | Self-assembled PLL crosslinked by poly-GA | N/A | N/A | B + E | <200 | N/A | Imaging of mice injected with nanogels-loaded DC | N/A |
|
| MRI (19F) | 19F-TFEMA | Part of polymer matrix | Poly-(DEAMA- | pH | Signal is turned “On” as pH decrease | A | 63 (pH 7.4) and 90 (pH 6.5) | N/A | N/A | N/A |
|
Formulation methods: refer to Fig. 1.
Fig. 3pH- and temperature-sensitive nanogels as dual T 2 and optical imaging agents. (A) Cy5.5-Lf-MPNA: P(NIPAM-co-AA) nanogels encapsulating Fe3O4 nanoparticles and conjugated with Cy5.5-labeled lactoferrin as a glioma-targeting ligand. (B) Thermo- and pH-responsive change in nanogel size (due to change in hydrophobicity). (C) In vivo MR and ex vivo NIR fluorescence imaging showed higher uptake of Cy5.5-Lf-MPNA than MPNA (without Cy5.5-labeled lactoferrin) in rat glioma.
PET imaging agents
| Imaging modality | Dye/contrast agent | Means of incorporation | Polymer components | Responsive size change | Responsive imaging property | Formulation method | Size (nm) | Targeting group | Cells/ | Therapeutics | Ref. |
| PET | 99mTc labeled 1-hexylcarbamoyl-5-fluorouracil (HCFU) | Encapsulation | Poly-(NIPAAM- | N/A | N/A | A | 50 | N/A | Biodistribution imaging of rabbits | HCFU |
|
| PET + UV fluorescence | 68Ga-NODAGA Alexa Fluor 488 | Conjugation Conjugation | Star-shaped PEG crosslinked by disulfide bond | Reducing environment | N/A | B | 290 | N/A | Uptake in monocytes | N/A |
|
| PET | 64Cu-NOTA | As crosslinker | PAA chemically crosslinked with NOTA crosslinkers | N/A | N/A | A | 63 | N/A | Imaging of 4T1 tumor and metastasis of mice | N/A |
|
| PET | [18F]-labelled BoHc/A | Conjugation to encapsulated drugs | Amino group- and cholesteryl-group-bearing pullulan (cCHP) | N/A | N/A | C | 40 | N/A | Imaging delivery to nasal mucosa of mice | BoHc/A |
|
| PET + visible light | 68Ga-DOTA NaYF4:Yb/Er/Tm UCNP | Conjugation As core from wit polymer was build on | PEI (coated on UCNP), conjugated with PEG | N/A | N/A | E | 136 | RGD | Imaging of M21 tumor bearing mice | N/A |
|
| PET + NIR | 64 Cu-DOTA Cy5.5 | Conjugation Conjugation | 5β-Cholanic acid and azide groups modified glycol chitosan | N/A | NIR turned ON upon cleavage of MMP-sensitive peptide | C | ∼300 | MMP-sensitive peptide | Imaging of A549 tumor in mice | N/A |
|
| PET + NIR | 124I-labeled chlorophyll-a cyanine dye | Encapsulation Conjugation | PAA | N/A | — | A | 18–25 | N/A | Imaging of Colon26 tumors in mice | Chlorophyll-a (PDT) |
|
Formulation methods: refer to Fig. 1.
Fig. 464Cu-bearing polyacrylamide (PAAm) nanogels as PET imaging nanogels. (A) Structures of three metal-chelating crosslinkers: DTPA (1), DOTA (2) and NOTA (3)-based. (B) Acrylamide was used as monomer and either 1, 2, or 3 was used as crosslinker to formulate nanogels (PAA/1, PAA/2 or PAA/3). (C) PET-CT imaging of mice with 4T1 tumors at 4 h, 24 h and 48 h after injection with PAA/2, PAA/3 or free 64Cu2+. Arrows indicate tumors. (D) Tumor/muscle ratio of PET signal. (E) PET imaging (arrows indicate popliteal lymph node in leg and primary tumor on shoulder) at 24 or 48 h post-injection.
UV-vis imaging agents with QD or Au/Ag nanoparticles
| Imaging modality | Dye/contrast agent | Means of incorporation | Polymer components | Responsive size change | Responsive imaging property | Formulation method | Size (nm) | Targeting group | Cells/ | Therapeutics | Ref. |
| UV-vis | Fe3O4 QD | As core from which polymer was built on | Chitosan | pH | N/A | E | 160 | N/A | Uptake in L02 cells | Insulin |
|
| UV-vis | QD | Electrostatic interaction and chemical crosslinks with polymer matrix | CM-dextran and PLL | N/A | N/A | D + E | 190 | N/A | N/A | N/A |
|
| UV-vis | QD | Electrostatic interaction between HA and QD | HA | N/A | N/A | E | 50–120 | HA | Imaging of lymphatic vessels on ears of mice | N/A |
|
| UV-vis | QD |
| Chitosan and PMAA crosslinked with MBA | pH | Photoluminescence (PL) increase as pH decreases | A + D | 85–175 | N/A | Uptake and cytoxicity on mouse melanoma B16F10 cells | Temozolomide |
|
| UV-vis | QD | Electrostatic interaction | Cholesterol-bearing amino-group-modified Pullulan | N/A | N/A | C + E | 38 | N/A | Uptake in HeLa cells | N/A |
|
| UV-vis | QD | Electrostatic interaction between lysosome, QD and polymer | Carboxymethyl cellulose | N/A | PL decreases as pH decreases | D + E | 285 | — | Uptake and cytotoxicity on HepG2 & MCF-7 cells | Methotrexate |
|
| NIR | QD |
| HPC and PAA crosslinked wit MBA | pH and temperature | PL increases as pH decreases | A + D | 32–50 (pH 4.5) to 75–83 (pH 7.4) | N/A | Cytotoxicity on B16F10 cells | Temozolomide |
|
| UV-vis | QD | As core from which polymer was built on | His-tagged polypeptides | pH, temperature and competitors | N/A | E | 40.2 | RGD | Uptake and cytotoxicity on HeLa cells | Dye ABDPSP & fluorescein sodium (model drugs) |
|
| UV-vis | Carbon shell and magnetic core nanoparticles | As core from which polymer was built on | Poly(NIPAM-AAm) crosslinked with MBA | NIR/magnetic induced thermal responsive | PL increases as temperature increase | A + E | 320 (at 24 °C) | — | Cytotoxicity of B16F10 cells | Curcumin |
|
| UV-vis | Ag NP | As core from which polymer was built on | Poly(NIPAM-AA) crosslinked with MBA | pH | Blue shift and increase in absorption intensity as pH decreases | A + E | ∼77 (pH 5.0) to ∼137 (pH 7.4) at 37 °C | — | Uptake and cytotoxicity on B16F10 cells | Dipyridamole |
|
| UV-vis | Au NP | As core from which polymer was built on | P(NIPAAM- | Visible light induced thermal responsive | N/A | A + E | >80 (37 °C) and ∼53 (25 °C) | N/A | Uptake and cytotoxicity of HeLa cells | 5-Fluorouracil |
|
| UV-vis | Au–Ag NP | As core from which polymer was built on | PEG crosslinked with PEGMA | NIR induced thermal responsive | PL increases as temperature increases | A + E | 18–43 (37 °C) | HA | Uptake and cytotoxicity on B16F10 cells | Temozolomide |
|
| UV-vis | Au–Ag NP | As core from which polymer was built on | PS crosslinked with DVB and PEG crosslinked with PEGMA | NIR induced thermal responsive | N/A | A + E | 22–37 (37 °C) | N/A | Uptake and cytotoxicity on B16F10 cells | Curcumin |
|
| UV-vis | Au NP |
| Lysosome–dextran | N/A | N/A | C | 190 | N/A | Uptake and cytotoxicity on KB cells | Doxorubicin |
|
| UV-vis | Au NP | As core from which polymer was built on | Chitosan and PAA crosslinked with glutaldehyde | N/A | N/A | D + A | ∼120 | N/A | Uptake and cytotoxicity on HepG2 cells | N/A |
|
| UV-vis | Au NP |
| Chitosan | N/A | N/A | B | 80–230 | N/A | — | N/A |
|
Formulation methods: refer to Fig. 1.
Fig. 5QD-encapsulating nanogels as lymph node imaging agents. (A) Synthesis and formulation scheme of HA-QD nanogels. (B) Image of a mouse ear under UV lamp 30 minutes after subcutaneous injection of HA-QD. (C) Fluorescence images of lymphatic vessels under microscope 30 minuets after injection of either HA-QD or QD. HA-QD provides a clear delineation of lymphatic vessel.
UV-vis/NIR imaging agents with fluorescent dyes
| Imaging modality | Dye/contrast agent | Means of incorporation | Major polymer backbone | Responsive size change/degradability | Responsive imaging property | Formulation method | Size (nm) | Targeting group | Cells/ | Therapeutics | Ref. |
| UV-vis | 5-Aminofluorescein (5-AF), 7-amino-4-methyl coumarin (AMC), or QDs | Conjugation | Chitosan and PAA crosslinked with MBA | N/A | N/A | A + D | 180 | N/A |
| Doxorubicin, or Vascular endothelial growth factor C |
|
| UV-vis | Fluorescein isothiocyanate | Conjugation | Poly(amidoamine) dendrimers and alginate crosslinked with Ca2+ | pH | N/A | E + B | 433 | N/A | Uptake and cytotoxicity on CAL-72 cells | Doxorubicin |
|
| UV-vis | 8-Hydroxypyrene-1-carbaldehyde (HPC) | Encapsulation | Polyurethane | — | Change in emission wavelength as a function of pH | B | 92 | N/A | Uptake in NIH/3T3 fibroblast cells | N/A |
|
| UV-vis/NIR | DMDP-M | Encapsulation | Crosslinked Pluronic F127 | — | Fluorescence turned “on” in presence of thiols | B | 45 | N/A | Uptake in NIH/3T3 fibroblasts | N/A |
|
| UV-vis | Self-fluorescent abietane | As part of polymer matrix | Poly(abietane methacrylate) crosslinked with PEGDA | N/A | N/A | A | 90–135 | Folic acid | Uptake in MCF-7 cells | Doxorubicin |
|
| UV-vis | Self-fluorescent ALC linker | Electrostatic encapsulation | Branched PEI crosslinked by aldehyde- | Thiols | Decrease in pH and presence of reducing agents lowers the fluorescence | B | 200 | N/A | Transfection in multiple cell lines | pDNA |
|
| UV-vis | Rhodamine B | As part of polymer matrix | P(NIPAM- | Temperature | Increased in fluorescence in presence of Cr3+ and increased temperature | A | 117 (20 °C) and 50 (40 °C) | N/A | N/A | N/A |
|
| NIR fluorescence | Cyanine dye | Conjugation | Azide-functionalized PEG methyl ether crosslinked with | Reducing environment | N/A | B | 210 | N/A | N/A | Doxorubicin |
|
| NIR-797 isothiocyanate | Conjugation | Methacrylated carboxymethyl cellulose crosslinked with disulfide linkage-containing crosslinkers | Reducing environment | N/A | B | 192 | N/A | NIR fluorescence imaging of H22 tumor-bearing mice | Doxorubicin |
| |
| IRDye800 | Conjugation | Amine-cholesteryl-group-bearing pullulan | N/A | N/A | C | 30 | N/A | SLN Mapping in mice and pigs | N/A |
| |
| ICG | Conjugation | ICG–HA conjugate | HAdase | Fluorescence turn “On” in presence of HAdase | C | 189 | HA | Tumor and SLN imaging of MDA-MB-231 tumor bearing mice | N/A |
| |
| ICG | Conjugation | Self-assembled ICG–HA conjugate with surface further crosslinked with disulfide linkage-containing crosslinkers | HAdase | Fluorescence turn “On” in presence of HAdase | C + B | 293 | N/A | Imaging of front paw of mice that are injected with nanogels pre-incubated with HAdase | N/A |
| |
| ICG | Conjugation | HA + poly(beta-amino)ester (PBAE) + ICG | pH | Fluorescence turn “On” in presence of HAdase | D | 73 (pH 7.4) and 15 (pH 5.5) | HA | Uptake in MDA-MB-231 breast cancer cells | N/A |
| |
| Ga-porphyrin | As crosslinkers | α,ω-Diazide/hydroxyl PEG and α,ω-difolate/azidePEG crosslinked by Ga-TPPPP | N/A | — | B | 110 | Folate | — | N/A |
|
Formulation methods: refer to Fig. 1.
Fig. 6Cellulose-based nanogels for NIR tumor imaging. (A) Synthesis of disulfide crosslinkers (CBA), methacrylated cellulose (MACMC) and formulation of nanogels encapsulating doxorubicin (Dox) through radical polymerization. NIR-797 isothiocyanate was conjugated to render nanogels with NIR emitting properties. (B) Real-time NIR imaging of subcutaneous hepatic H22 tumor-bearing mice injected with NIR nanogels at 120 h post-injection. White circle highlights the tumor. (C) Tumor size was substantially decreased upon multiple dosage of Dox-containing nanogels compared with controls. (dosage time indicated by arrows). Saline, free Dox, and nanogels formulated with bisacrylamide (MACMC–MBA–Dox) without reduction-sensitive drug release were injected as controls.